Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedAug 12, 2026
DataAggregated Company Financials
Companies20
  • 7D0.6%
  • 3M4.3%
  • 1Y-2.7%
  • YTD-6.8%

In the last week, the Healthcare industry is up 1.4%, with Genmab up 6.1%. However, the industry is down 3.4% over the past year. Earnings are forecast to grow by 3.2% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 12 Aug 2026DKK 1.8tDKK 472.2bDKK 141.4b23.1x12.8x3.8x
Fri, 10 Jul 2026DKK 1.9tDKK 469.2bDKK 147.1b21.1x12.6x4x
Sun, 07 Jun 2026DKK 1.7tDKK 468.9bDKK 147.1b19.7x11.4x3.6x
Tue, 05 May 2026DKK 1.7tDKK 447.5bDKK 130.0b19x12.9x3.7x
Thu, 02 Apr 2026DKK 1.5tDKK 447.6bDKK 130.0b17.4x11.3x3.3x
Sat, 28 Feb 2026DKK 1.5tDKK 447.7bDKK 131.0b18.7x11.4x3.3x
Mon, 26 Jan 2026DKK 2.3tDKK 453.5bDKK 136.8b18.4x16.7x5x
Wed, 24 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Fri, 21 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b17x13.9x4.2x
Sun, 19 Oct 2025DKK 2.0tDKK 447.5bDKK 141.7b19x14.4x4.5x
Tue, 16 Sep 2025DKK 2.1tDKK 447.3bDKK 141.6b19.5x14.6x4.6x
Thu, 14 Aug 2025DKK 1.9tDKK 434.8bDKK 132.2b28.8x14.3x4.4x
Sat, 12 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.3x19.9x5.9x
Mon, 09 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Wed, 07 May 2025DKK 2.4tDKK 409.8bDKK 121.1b22.8x20x5.9x
Fri, 04 Apr 2025DKK 2.5tDKK 409.4bDKK 121.3b23.5x20.5x6.1x
Sun, 02 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Tue, 28 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.1x29.8x8.6x
Thu, 26 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.8x29.5x8.5x
Sat, 23 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35x10.1x
Mon, 21 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.1x38.8x11.2x
Wed, 18 Sep 2024DKK 4.6tDKK 371.9bDKK 107.1b36.3x43.1x12.4x
Fri, 16 Aug 2024DKK 4.7tDKK 370.7bDKK 106.9b37.1x44.3x12.8x
Sun, 14 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Tue, 11 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b35.9x46.5x13.9x
Thu, 09 May 2024DKK 4.5tDKK 355.3bDKK 106.5b34.6x42.3x12.7x
Sat, 06 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.7x13x
Mon, 04 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38x44.4x12.9x
Wed, 31 Jan 2024DKK 3.9tDKK 320.8bDKK 90.1b31.5x42.8x12x
Fri, 29 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b33.1x40.4x11.3x
Sun, 26 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Tue, 24 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.6x42.9x11.5x
Thu, 21 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b35.9x42.6x11.5x
Sat, 19 Aug 2023DKK 3.3tDKK 303.2bDKK 81.1b36.8x40.9x10.9x
Price to Earnings Ratio

40.9x


Total Market Cap: DKK 3.3tTotal Earnings: DKK 81.1bTotal Revenue: DKK 303.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 28.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.7x which is lower than its 3-year average PE of 28.3x.
  • The 3-year average PS ratio of 8.2x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 20% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market0.16%
Healthcare0.63%
Life Sciences8.81%
Biotech5.30%
Medical Equipment1.32%
Pharma-0.0067%
Healthcare Services-0.35%
Healthtech-1.20%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.8x.
    • Analysts are expecting annual earnings growth of 21.0%, which is higher than its past year's earnings growth of 5.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 7.7% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.99k6.1%
+DKK 3.7b		44.0%PE23.3x
COLO B ColoplastDKK 440.402.0%
+DKK 1.9b		-27.3%PE47.1x
ZEAL Zealand PharmaDKK 335.105.3%
+DKK 1.2b		-2.3%PE3.7x
CHEMM ChemoMetecDKK 475.0013.9%
+DKK 1.0b		-5.4%PE46.7x
HLUN B H. LundbeckDKK 41.482.5%
+DKK 991.2m		17.7%PE11x

Latest News

CHEMM
DKK 475.00
ChemoMetec
7D
13.9%
1Y
-5.4%
NOVO B
DKK 307.20
Novo Nordisk
7D
-0.1%
1Y
-4.1%
Narrative Update • Aug 10

NOVO: From Hypergrowth to Execution Mode

10.08.2026 New CEO Mike Doustdar: His strength lies less in building factories and more in building markets. From my perspective, the share price has been driven by a lot of exaggeration.
GMAB
DKK 1,993.00
Genmab
7D
6.1%
1Y
44.0%
Analysis Article • Aug 09

Genmab A/S Just Beat EPS By 29%: Here's What Analysts Think Will Happen Next

It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...
BAVA
DKK 177.10
Bavarian Nordic
7D
-1.2%
1Y
-25.4%
ALK B
DKK 221.40
ALK-Abelló
7D
1.5%
1Y
20.7%
GUBRA
DKK 378.00
Gubra
7D
2.7%
1Y
8.4%
DEMANT
DKK 284.20
Demant
7D
-0.1%
1Y
12.2%
Narrative Update • Aug 04

DEMANT: Future Returns Will Hinge On Executing Margin And Revenue Mix Improvements

The analyst price target for Demant has moved from DKK 251 to DKK 277, as analysts factor in updated assumptions on revenue growth, margins and valuation following a mix of target hikes and rating changes across recent research. Analyst Commentary Recent research on Demant shows a mix of optimism and caution, with higher price targets sitting alongside more neutral ratings.
HLUN B
DKK 41.48
H. Lundbeck
7D
2.5%
1Y
17.7%
EMBLA
DKK 29.90
Embla Medical hf
7D
4.9%
1Y
-2.6%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
ZEAL
DKK 335.10
Zealand Pharma
7D
5.3%
1Y
-2.3%
Narrative Update • Jul 23

ZEAL: Future Returns Will Hinge On Obesity Pipeline Execution Timing

The updated analyst price target for Zealand Pharma moves to DKK 300 from DKK 400. This reflects a more cautious stance as analysts point to fewer near term catalysts, lower peak sales expectations for petrelintide and survodutide, and a higher assumed discount rate and future P/E in their models.
COLO B
DKK 440.40
Coloplast
7D
2.0%
1Y
-27.3%
Narrative Update • Jul 15

COLO B: Recent P/E Reset Will Create Upside Opportunity

Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
SMSMED
DKK 2.87
Scandinavian Medical Solutions
7D
-0.3%
1Y
-36.9%
BIOPOR
DKK 1.16
BioPorto
7D
-1.3%
1Y
-10.8%
NNIT
DKK 37.85
NNIT
7D
-1.4%
1Y
-38.0%
STENO
DKK 0.97
Stenocare
7D
-0.8%
1Y
32.6%
VIRO
DKK 9.25
ViroGates
7D
-18.9%
1Y
-7.5%